September 19, 2012
Eli Lilly Japan announced on September 14 that it has filed an application for Strattera Oral Solution 0.4% (atomoxetine), as a new formulation for the attention deficit/hyperactivity disorders (AD/HD) treatment Strattera Capsules. To date, Strattera has only been marketed in...read more